RT @dresalmeri: Se probó empagliflozina en cerdos no diabéticos sometidos experimentalmente a isquemia miocárdica y el grupo tratamiento pr…
Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics. https://t.co/6IFBlN65LV “...nondiabetic porcine model. Empagliflozin switches myocardial fuel utilization away from glucose towar
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @yulnunezvill: Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energe…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
Se parece a una dieta que yo me sé...
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @mbotana: 3.- Ayuda a explicar la diferencia de morbimortalidad CV entre los estudios con iSGLT2 que incluyen más población en prevenció…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
I agree. SGLT2 inhibitors have the potential of being game-changing therapies primarily for heart failure and renal disease that also happen to be mild antidiabetics. Lot of exciting research still ahead of us! Many patients who could benefit from this pha
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
Turning into a miracle drug for CVD and MD:https://t.co/Tj9AF4DSSf
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
La dieta ketogenica tiene beneficios que modulan al sistema cardiovascular.
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @yulnunezvill: Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energe…
RT @yulnunezvill: Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energe…
RT @yulnunezvill: Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energe…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @yulnunezvill: Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energe…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @yulnunezvill: Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energe…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @yulnunezvill: Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energe…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @yulnunezvill: Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energe…
Earlier than later we should start using it in non diabetics patients... Just matter of time & trials.
【ブタ:SGLT2阻害薬が左室リモデリング抑制/ JACC】 左前下行枝結索HFモデル2カ月観察:SGLT2阻害薬群で、対照に比べ、LVリモデリングが減弱。対照とは異なり、非梗塞部位での糖利用は増えず、ケトン体、FFA、分枝鎖アミノ酸の利用が増。心筋ATPも増。 https://t.co/FbGpV1oEPe
RT @DrRyanPDaly: Interesting is it just me? I gotta say their does seem to be overlapping physiology between this and ketogenic diets. http…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
Interesting is it just me? I gotta say their does seem to be overlapping physiology between this and ketogenic diets.
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @glucotoxicidad: Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Ener…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co/V6rOnFyp8L https://t.co/0LZZEub3S7
RT @bassbarajas: Efecto de los SGLT-2 a 2 meses sobre remodelado cardiaco en modelo animal. La historia de los SGLT-2 y su posible relació…
RT @josalar13: Muy buen trabajo d mejoria metabol. cardiaco con empaglifloz. en Ins. Cardiaca,demostrado en experimental con cerdos,del gr…
RT @cristinatejerap: Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Ene…
RT @yulnunezvill: Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energe…
RT @yulnunezvill: Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energe…
RT @ValleAlfonso: Empagliflozin ⤵️ adverse cardiac remodeling and HF in a nondiabetic porcine model. Empagliflozin improving myocardial ene…
RT @yulnunezvill: Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energe…
RT @yulnunezvill: Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energe…
RT @mbotana: 3.- Ayuda a explicar la diferencia de morbimortalidad CV entre los estudios con iSGLT2 que incluyen más población en prevenció…
RT @cristinatejerap: Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Ene…
RT @bassbarajas: Efecto de los SGLT-2 a 2 meses sobre remodelado cardiaco en modelo animal. La historia de los SGLT-2 y su posible relació…
RT @yulnunezvill: Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energe…
RT @yulnunezvill: Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energe…
RT @yulnunezvill: Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energe…
RT @bassbarajas: Efecto de los SGLT-2 a 2 meses sobre remodelado cardiaco en modelo animal. La historia de los SGLT-2 y su posible relació…
RT @yulnunezvill: Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energe…
RT @yulnunezvill: Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energe…
RT @yulnunezvill: Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energe…
RT @mbotana: 3.- Ayuda a explicar la diferencia de morbimortalidad CV entre los estudios con iSGLT2 que incluyen más población en prevenció…
RT @yulnunezvill: Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energe…
RT @yulnunezvill: Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energe…
RT @yulnunezvill: Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energe…
RT @yulnunezvill: Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energe…